To counteract this, researchers have developed a dual inhibitor, GCCSysm-4 (G-4), which simultaneously inhibits YAP and COX-2 activity, significantly enhancing the sensitivity of CRC cells to chemotherapeutic agents (52). The gene discussed is PTGS2; the disease is colorectal carcinoma.